----
Current ValuationThe current P/E ratio is 22.78, within the reasonable range, cheaper than 71.55% of the time in the past 5 years, and the industry ranks 37/256, the industry Median -1.11.
22.78xP/E
$151.91Stock price
$6.67Earnings per share
22.78xP/E
Stock price$151.91Earnings per share$6.67
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 33.96x
- Typical range
- 17.87x–48.03x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0295887116
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
RHHVFUSROCHE HOLDINGS AG | 26.66x | -- | $411.79B |
RHHBYUSRoche | 25.24x | -- | $389.91B |
NVSUSNOVARTIS AG | 22.52x | 0.87% | $287.24B |
AZNUSAstraZeneca | 25.46x | -- | $265.97B |
SNYNFUSSanofi | 21.66x | -- | $99.35B |
SNYUSSanofi | 21.73x | 23.14% | $99.68B |
CHGCYUSChugai Pharmaceutical | 23.53x | -- | $70.88B |
MKKGYUSMerck | 25.39x | -- | $69.74B |
UCBJYUSUCB S.A. | 22.78x | -- | $57.93B |
HLNUSHaleon | 20.89x | 1.54% | $45.23B |
LQDAUSLiquidia Tech | 27.54x | 354.53% | $3.82B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
